Meulendijks, Didier <br/><br/>
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2016 
 - 858-67 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-15-1506  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--pharmacokinetics<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--pharmacokinetics<br/>Biomarkers, Tumor--blood<br/>Chemokine CCL2--blood<br/>Colorectal Neoplasms--blood<br/>Cytokine TWEAK<br/>Female<br/>Gene Expression<br/>Humans<br/>Male<br/>Matrix Metalloproteinase 9--blood<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Receptors, Tumor Necrosis Factor--blood<br/>TNF Receptor-Associated Factor 1--metabolism<br/>TWEAK Receptor<br/>Treatment Outcome<br/>Tumor Necrosis Factor Inhibitors<br/>Young Adult